Printer Friendly

PRESENTATION OF PRELIMINARY DATA ON 3TC IN THE TREATMENT OF HIV INFECTION AT THE INTERNATIONAL CONFERENCE ON AIDS IN AMSTERDAM

 PRESENTATION OF PRELIMINARY DATA ON 3TC IN THE TREATMENT OF HIV
 INFECTION AT THE INTERNATIONAL CONFERENCE ON AIDS IN AMSTERDAM
 LAVAL, Quebec, July 20 /PRNewswire/ -- BioChem Pharma (NASDAQ: BCHXF) today issued the following: During the International Conference on AIDS in Amsterdam, researchers are presenting preliminary clinical information on the reverse transciptase inhibitor, 3TC, currently in development for the treatment of HIV infection.
 Two presentation provide data from ongoing Phase I/II trials in which over 170 European and North American patients received doses of between 0.5 mg/kg and 12 mg/kg per day. The trials began in August 1991 in Europe and September 1991 in North America.
 3TC has been well tolerated in asymptomatic as well as in ARC (AIDS related complex) and AIDS patients although the data from the higher doses is from a limited number of patients and for a short duration. The changes in surrogate markers, such as CD4 cells, P24 antigen, B-2 microglobulin and neopterin have shown encouraging trends which appear to indicate that 3TC has anti-viral activity across the dose range.
 Given the relatively small study population and the variability of the principal marker CD4, more data are being generated before proceeding to Phase II/III clinical trials. In August it is proposed to move to a higher dose with the hope that an appropriate dose can be chosen before the end of this year, and allow the Phase II/III studies to begin in early 1993. As previously announced, and NDA submission in 1994 is still on target.
 Glaxo continues to pursue the development of 3TC with the highest priority, but it is too early to be sure of the ultimate role of the compound in the treatment of HIV infection.
 BioChem Pharma Inc. is engaged in the research and development of therapeutic products and the research, development, manufacturing and marketing of vaccine and diagnostic products for a broad range of infectious and other diseases. Its shares are listed on the Montreal and Toronto stock exchanges (BCH) and on the NASDAQ exchange.
 -0- 7/20/92
 /CONTACT: Dr. Francesco Bellini, president and chief executive officer of BioChem Pharma, 514-681-1744; Barbara Dawson of Glaxo Canada, 416-819-3020; or Michele Roy or Gerard Berube of NATIONAL Public Relation, 514-843-7171, for BioChem Pharma/
 (BCHXF) CO: BioChem Pharma Inc.; Glaxo Canada Inc. ST: Quebec IN: MTC SU:


SH-LR -- NY013 -- 0617 07/20/92 09:55 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1992
Words:399
Previous Article:TERADYNE RELEASES SECOND QUARTER RESULTS
Next Article:FIRST AUSTRALIA PRIME INCOME FUND ANNOUNCES DIVIDEND
Topics:


Related Articles
EXCITING RESULTS WITH MERCK'S CRIXIVAN(R) COULD CHANGE THE WAY DOCTORS TREAT HIV DISEASE AND AIDS
INVESTIGATIONAL COMPOUND SHOWS PROMISE PRELIMINARY DATA SUGGESTS
INVESTIGATIONAL THREE-DRUG REGIMEN ADDS FURTHER SUPPORT FOR POTENTIAL BENEFITS OF COMBINATION THERAPY
DATA SUGGEST POSSIBLE UTILITY OF INVESTIGATIONAL THREE-DRUG COMBINATION FOR TREATMENT OF PRIMARY HIV INFECTION
AIDS Clinical Trial Group (ACTG) To Conduct Clinical Study of 141W94/VX-478, an HIV Protease Inhibitor
Phase III Pivotal Clinical Trial Begins with 141W94/VX-478, a Protease Inhibitor Designed by Vertex for Treatment of HIV Infection and AIDS
Clinical Benefit Confirmed for Epivir(TM)(lamivudine; 3TC) in FDA Decision;
New Studies with Crixivan Presented at ICAAC: Crixivan in Triple Therapy Lowered HIV to Undetectable Levels for Two Years in Approximately 80 Percent...
Vertex Pharmaceuticals Reports Encouraging Preliminary Data from Phase II Clinical Study with HIV Protease Inhibitor 141W94
BIOCHEM PHARMA RECEIVES GO-AHEAD FROM U.S. FDA TO START PHASE I CLINICAL TRIAL WITH ITS NOVEL ANTI-HIV COMPOUND, BCH-10652

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters